MHX Jakarta 18-21 July 2024 Wrapped Up with Record Turnout, High Leads Generation and Strategic Partnerships
JAKARTA, Indonesia, July 26, 2024 /PRNewswire/ -- Malaysia Healthcare Travel Council (MHTC) achieved impressive results in numerous fronts in Jakarta! MHTC is the pioneer in organising healthcare expo in Indonesia and the inaugural event was in Semarang in 2012. MHTC has successfully organised two events in Indonesia in the first half of...
ReviR Therapeutics Raises $30 Million Series A Financing to Advance its Proprietary Oral Genetic Medicines for Multiple CNS Disorders
BRISBANE, Calif., July 26, 2024 /PRNewswire/ -- ReviR Therapeutics, an AI-enabled biotechnology company focused on developing small molecule RNA modulators for neurogenetic diseases, announced today that it has successfully completed a $30 million Series A financing, bringing the total raised so far to $54M, including the seed financing in 2021. The financing was led by Lapam Capital with strong...
CStone Announces European Commission Approval of Sugemalimab (Cejemly®) as First-Line Treatment for Non-Small Cell Lung Cancer
Sugemalimab becomes the world's first anti-PD-L1 monoclonal antibody (mAb) approved in Europe for first-line treatment of both squamous and non-squamous non-small cell lung cancer (NSCLC), also marking the first successful international approval of a China domestic anti-PD-L1 mAb. The European Commission (EC) approval is based on the results of GEMSTONE-302 Phase 3 trial, which demonstrated that sugemalimab in...
MGI and HKBU Collaborate on Advanced Sequencing Technology to Combat Doping in Sports
PARIS, July 26, 2024 /PRNewswire/ -- MGI Tech Co., Ltd. ("MGI"), a company committed to building core tools and technologies that drive innovation in life science, today announced its collaboration with renowned geneticist, Professor Yannis Pitsiladis from Hong Kong Baptist University, on sports and anti-doping research. Utilizing MGI's state-of-the-art DNBSEQ sequencers...
HanAll Biopharma Reports Q2 2024 Financial Results and Provides Business Update
HanAll reports strong financial performance with second quarter total revenue of 31.6 billion KRW, driven by the strong sales from the key products. HanAll expands collaboration with Turn Biotechnologies through an exclusive licensing agreement for Epigenetic Reprogramming of Aging (ERATM) technology, targeting ophthalmic and otic diseases. Progress in clinical development programs...
Sanyou Bio Congratulates Eluminex Biosciences and Foreseen Biotechnology on Major Breakthroughs in Innovative Drug Project
SHANGHAI, July 26, 2024 /PRNewswire/ -- On July 15, Eluminex Biosciences announced that their tri-specific fusion antibody drug, EB-105, has administered its first dose to a diabetic macular edema patient in the United States. This clinical trial, known as LOTUS, is an open-label, multicenter, single-dose, dose-escalation clinical trial via intravitreal injection, currently being conducted in four hospitals across the...
Harbour BioMed to Present the Latest Progress of the First-in-Class Fully Human Anti-B7H7/HHLA2 Monoclonal Antibody HBM1020 at the ESMO Congress 2024
CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SUZHOU, China , July 26, 2024 /PRNewswire/ -- Harbour BioMed (the "Company"; HKEX: 02142), a global biopharmaceutical company committed to the discovery, development, and commercialization of novel antibody therapeutics focusing on oncology and immunology, announced today that the Company will release the latest clinical data on its first-in-class fully...
Innovent and WeComput Announce Strategic Partnership to Advance AI-Driven Drug Discovery and Development
SAN FRANCISCO and SUZHOU, China, July 26, 2024 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmune, ophthalmology and other major diseases, today announced a strategic partnership with WeComput to jointly advance the construction and improvement of Innovent Biologics' Artificial Intelligence...
Angel Yeast Showcases Innovative Yeast Protein Solutions at Growth Asia 2024
SHANGHAI, July 26, 2024 /PRNewswire/ -- Angel Yeast (SH600298), a global leader in yeast manufacturing, recently introduced its yeast protein and innovative application solutions at the Growth Asia 2024 summit, which was co-hosted by leading industry media NutraIngredients and FoodNavigator from July 16 to 18 in Singapore. Angel Yeast showcases innovative yeast...
Neurophet to launch total solution for AD treatments ‘Neurophet AQUA AD’ at AAIC 2024
- Demonstrates Neurophet AQUA AD for AD treatments such as Leqembi and Kisunla - Introduces updated version of Neurophet SCALE PET with centiloid scale feature SEOUL, South Korea, July 25, 2024 /PRNewswire/ -- Neurophet, an artificial intelligence (AI) solution company for brain disease, announced its participation in the Alzheimer's Association International Conference...
